Friday, February 17, 2012
Curis Inc., of Lexington, Mass., said partner Debiopharm Group, of Lausanne, Switzerland, initiated a Phase Ib expansion study of Debio 0932, a heat-shock protein 90 inhibitor that recently completed a Phase Ia dose-escalation study evaluating safety and maximum-tolerated dose.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.